Optimized crosslinkers for trapping a target on a substrate
Samuel Lai, Carrboro, NC (US); M. Gregory Forest, Chapel Hill, NC (US); Christine Henry, Chapel Hill, NC (US); Timothy Wessler, Durham, NC (US); Alexander Chen, Glenville, NY (US); Jennifer Schiller, Chapel Hill, NC (US); and Jay Newby, Carrboro, NC (US)
Assigned to The University of North Carolina at Chapel Hill, Chapel Hill, NC (US)
Filed by The University of North Carolina at Chapel Hill, Chapel Hill, NC (US)
Filed on Mar. 18, 2022, as Appl. No. 17/698,645.
Application 17/698,645 is a continuation of application No. 17/063,122, filed on Oct. 5, 2020, abandoned.
Application 17/063,122 is a continuation of application No. 15/977,432, filed on May 11, 2018, granted, now 10,793,623, issued on Oct. 6, 2020.
Application 15/977,432 is a continuation in part of application No. PCT/US2016/061574, filed on Nov. 11, 2016.
Claims priority of provisional application 62/254,856, filed on Nov. 13, 2015.
Prior Publication US 2022/0372116 A1, Nov. 24, 2022
1. A method for preventing or treating an infection by a viral pathogen including either a human immunodeficiency virus or a herpes virus in a vaginal mucosal extracellular matrix substrate in a subject, said method comprising: altering a binding affinity of a crosslinker to the vaginal mucosal extracellular matrix substrate to form a pool of candidate crosslinkers that binds to both the vaginal mucosal extracellular matrix substrate and to the viral pathogen; selecting an altered crosslinker that associates with the vaginal mucosal extracellular matrix substrate between 20% to less than 95% of the time, has a rate of binding to the viral pathogen greater than about 1×104 M−1 s−1, and has a diffusion coefficient that is between 20% to 99% less than a diffusion coefficient of the altered crosslinker in water; and administering the altered crosslinker to the subject, wherein the crosslinker comprises an antibody or portion of an antibody that binds to the viral pathogen.